Bohn, who directs Notre Dame’s Berthiaume Institute for Precision Health, joins a cohort of 42 new fellows selected for their “outstanding achievements in and contributions to science, the profession, and the Society.”
The fellows come from leading research universities, including the University of Chicago, the University of Pennsylvania, Cornell University, Princeton University, and the Georgia Institute of Technology and from industry leaders such as Dow, Bayer, and Pfizer.
Bohn is an internationally known leader in the field of precision health. His research and innovations focus on molecular nanotechnology, personal health monitoring, and the imaging of microbial communities.
“Paul Bohn is an innovative, interdisciplinary researcher who has demonstrated exceptional leadership here at Notre Dame,” said John T. McGreevy, the Charles and Jill Fischer Provost. “It is wonderful to see the American Chemical Society recognize his contributions to the field through his selection as a fellow.”
Bohn earned his bachelor’s degree in chemistry from Notre Dame in 1977 and a doctorate in chemistry from the University of Wisconsin-Madison. He was named one of the world’s top 20 analytical scientists in 2019. He has authored or co-authored over 300 publications and owns nine patents in technologies related to his work.
Brett Beasley / Writer and Editorial Program Manager
Notre Dame Research / University of Notre Dame
email@example.com / +1 574-631-8183
research.nd.edu / @UNDResearch
About Notre Dame Research:
The University of Notre Dame is a private research and teaching university inspired by its Catholic mission. Located in South Bend, Indiana, its researchers are advancing human understanding through research, scholarship, education, and creative endeavor in order to be a repository for knowledge and a powerful means for doing good in the world. For more information, please see research.nd.edu or @UNDResearch.
Originally published by research.nd.edu on August 08, 2023.at